Clinical use of hemostatic agents. 1978

G D Lowe, and D H Lawson

UI MeSH Term Description Entries
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D006490 Hemostatics Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. Antihemorrhagic,Hemostatic,Antihemorrhagics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000933 Antifibrinolytic Agents Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. Antifibrinolysin,Antifibrinolysins,Antifibrinolytic,Antifibrinolytic Agent,Antiplasmin,Antiplasmins,Antifibrinolytics,Plasmin Inhibitor,Plasmin Inhibitors,Agent, Antifibrinolytic,Agents, Antifibrinolytic,Inhibitor, Plasmin,Inhibitors, Plasmin
D014812 Vitamin K A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Related Publications

G D Lowe, and D H Lawson
March 1974, Zdravotnicka pracovnice,
G D Lowe, and D H Lawson
January 1974, Problemy gematologii i perelivaniia krovi,
G D Lowe, and D H Lawson
September 2014, Obstetrical & gynecological survey,
G D Lowe, and D H Lawson
January 2007, Digestive surgery,
G D Lowe, and D H Lawson
August 1983, The Journal of the Operating Room Research Institute : JORRI,
G D Lowe, and D H Lawson
September 1947, Surgical staff seminars. United States. Veterans Administration. Hospital, Minneapolis,
G D Lowe, and D H Lawson
July 2011, Dental clinics of North America,
G D Lowe, and D H Lawson
December 2004, Transfusion,
G D Lowe, and D H Lawson
March 1986, Fel'dsher i akusherka,
G D Lowe, and D H Lawson
April 2015, Journal of the American Dental Association (1939),
Copied contents to your clipboard!